ArticlePloS one2026
Genomic characterisation of extensively drug-resistant Acinetobacter baumannii isolates from a tertiary hospital in Ghana.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii (A. baumannii) is an emerging "superbug" whose infections have become extremely difficult to treat due to its diverse antimicrobial resistance mechanisms and resistance to last-resort antibiotics including carbapenems. Despite this, data on genetic determinants and genomic context of carbapenemase genes in A. baumannii are scarce in Ghana. This study investigated the genetic determinants of carbapenem resistance in clinical isolates of A. baumannii (Ab) and explored the genetic contexts of carbapenemase-encoding genes in extensively drug-resistant A. baumannii (XDR-Ab). We analysed 65 archived clinical A. baumannii isolates. Identification and antimicrobial susceptibility profiles of the isolates were determined using a MALDI-TOF-MS and the Microscan device, respectively. Carbapenem resistant A. baumannii (CR-Ab) isolates were screened for carbapenemase-encoding genes (blaNDM-1, blaKPC, blaVIM, blaOXA-48, blaOXA-23, blaOXA-58, and blaIMP) using loop-mediated isothermal amplification (LAMP). Six XDR-Ab isolates were whole-genome sequenced (WGS) using Nanopore MinION. Carbapenem resistance was observed in 18/65 (27.7%) isolates. All CR isolates were resistant to penicillins, cephalosporins, fluroquinolones, aminoglycosides, sulfonamides and carbapenems (minimum inhibitory concentrations, MICs, > 2µg/ml - > 8µg/ml). The most predominant resistance gene, blaNDM-1 (33.3%), was found to co-exist with blaOXA-23 (27.8%) or blaOXA-58 (16.7%), while blaOXA-420 (12.5%) was the least prevalent gene detected. The sequence types identified among the isolates were ST2 (33.3%), ST164 (16.7%), ST214 (16.7%), ST52 (16.7%), and ST16 (16.7%) according to MLST-Pasteur scheme. The study highlights the carriage of multiple carbapenemase genes, other AMR-encoding genes and efflux pumps in XDR clinical A. baumannii isolates. To the best of our knowledge, the study reports for the first time, the detection of ST2 OXA-23, NDM-1 and ST164 OXA-58, NDM-1-producing A. baumannii strains at the Korle Bu Teaching Hospital. These strains belong to high-risk clones and continuous surveillance through molecular epidemiological studies and public health interventions are urgently needed to control their spread in Ghana.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.